头颈部癌症患者放射性腮腺相关口干症的预测:再生加权剂量
研究利用1013例前瞻性随访的头颈部癌症根治性放疗患者的治疗与毒性数据,定义再生加权剂量Dreg PG=Dmean SCR区域+r×Dmean非SCR区域,在663例中构建口干症NTCP模型并在350例中验证。对侧腮腺剂量与日间、进食相关及医生评定的≥2级口干症相关,多数腮腺功能相关终点的r小于3.6,验证显示良好区分度与校准度。
要点
- 对侧腮腺剂量与日间、进食相关及医生评定的≥2级口干症相关。
- 多数腮腺功能相关终点的r小于3.6,SCR区域Dmean对口干症风险的贡献大于Dmean PG的预测。
- 验证显示模型具有良好区分度与校准度。
核心结论
- 开发了干细胞保护性放疗的临床实施工具:考虑腺体内放射敏感性区域差异的腮腺再生加权剂量,以及纳入该新剂量指标和其他预后因素的NTCP模型。
研究设计与样本
- 使用1013例前瞻性随访的接受根治性放疗的头颈部癌症患者的治疗与毒性数据。
- 在先前发表的测试干细胞保护性放疗试验的102例患者中估计r的最具预测价值。
- 在每个终点,使用Dreg PG、其他器官剂量和临床因素,在663例患者中通过多变量逻辑回归分析开发NTCP模型。
- 模型在350例患者中进行验证。
主要发现
- 对侧腮腺剂量与日间、进食相关及医生评定的≥2级口干症相关。
- 多数腮腺功能相关终点的r估计小于3.6。
- SCR区域Dmean对口干症风险的贡献大于Dmean PG的预测。
- 其他常被选中的预测因素为治疗前口干症和口腔Dmean。
- 验证显示良好区分度与校准度。
关键数值与推荐
- 再生加权剂量定义为Dreg PG=Dmean SCR区域+r×Dmean非SCR区域,其中Dreg为再生加权剂量,Dmean为平均剂量,r为权重因子。
- 考虑这些区域体积不同,Dreg PG中r>3.6表明SCR区域效应增强。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite improvements to treatment, patients with head and neck cancer (HNC) still experience radiation-induced xerostomia due to salivary gland damage. The stem cells of the parotid gland (PG), concentrated in the gland's main ducts (stem cell rich [SCR] region), play a critical role in the PG's response to radiation. Treatment optimization requires a dose metric that properly accounts for the relative contributions of dose to this SCR region and the PG's remainder (non-SCR region) to the risk of xerostomia in normal tissue complication probability (NTCP) models for xerostomia. MATERIALS AND METHODS: Treatment and toxicity data of 1013 prospectively followed patients with HNC treated with definitive radiation therapy (RT) were used. The regeneration-weighted dose, enabling accounting for the hypothesized different effects of dose to the SCR and non-SCR region on the risk of xerostomia, was defined as Dreg PG = Dmean SCR region + r × Dmean non-SCR region, where Dreg is the regeneration-weighted dose, Dmean is the mean dose, and r is the weighting factor. Considering the different volumes of these regions, r > 3.6 in Dreg PG demonstrates an enhanced effect of the SCR region. The most predictive value of r was estimated in 102 patients of a previously published trial testing stem cell sparing RT. For each endpoint, Dreg PG, dose to other organs, and clinical factors were used to develop NTCP models using multivariable logistic regression analysis in 663 patients. The models were validated in 350 patients. RESULTS: Dose to the contralateral PG was associated with daytime, eating-related, and physician-rated grade ≥2 xerostomia. Consequently, r was estimated and found to be smaller than 3.6 for most PG function-related endpoints. Therefore, the contribution of Dmean SCR region to the risk of xerostomia was larger than predicted by Dmean PG. Other frequently selected predictors were pretreatment xerostomia and Dmean oral cavity. The validation showed good discrimination and calibration. CONCLUSIONS: Tools for clinical implementation of stem cell sparing RT were developed: regeneration-weighted dose to the parotid gland that accounted for regional differences in radiosensitivity within the gland and NTCP models that included this new dose metric and other prognostic factors.
引用
- van Rijn-Dekker MI, van Luijk P, Schuit E, et al. Prediction of Radiation-Induced Parotid Gland-Related Xerostomia in Patients With Head and Neck Cancer: Regeneration-Weighted Dose. Int J Radiat Oncol Biol Phys. 2023. PMID: 37150262. doi:10.1016/j.ijrobp.2023.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。